Selpercatinib (Retevmo) – targeted treatment review for RET-positive tumors

What selpercatinib is in simple patient language

Retevmo is the brand name. Selpercatinib is the drug name in medical records. A cancer capsule. A RET blocker. Not classic chemotherapy. Not immunotherapy. Not a capsule to start just because one old report says “RET”.

This drug comes up when the tumor file shows a real RET change. The report has to say what was found: a fusion, a mutation, or another RET result that the oncologist can use. Without that, the name Retevmo does not mean much.

The first talk should stay practical. Where is the disease now? What was already tried? Any pressure spikes? Any irregular pulse, liver trouble, bleeding, or surgery lately? Those facts can move the answer.

How selpercatinib works

Some tumor cells use RET as a growth signal. When that signal stays switched on, the cell keeps getting a message to grow and survive.

Selpercatinib tries to quiet that RET message. If the tumor is really using this route, scans may improve. Sometimes the quieter result is just as useful for a time: the disease stops moving so fast.

The same capsule can also create problems outside the tumor. Blood pressure may rise. Liver tests may move. The heartbeat can matter. A wound may heal more slowly. That is why the checkup is not only about the scan.

Which diseases or situations selpercatinib may be used for

Selpercatinib belongs in the conversation only when RET is part of the case. The organ name alone is not enough.

• lung cancer where the report clearly names a RET rearrangement or fusion
• medullary thyroid cancer when the file shows a RET mutation
• thyroid cancer with a RET fusion when local treatment is no longer the main answer
• some advanced solid tumors where RET is the real driver in the report
• a later treatment step after older plans have stopped helping
• a second opinion when Retevmo was offered but the reason is not clear

Two patients can carry similar words in the diagnosis and still need different plans. Past treatment, speed of disease, heart rhythm, pressure, liver values, wounds, and daily strength all matter.

When selpercatinib can be especially relevant

Retevmo usually enters the discussion after the molecular report gives the doctor something real to work with. Then the question becomes simple enough: can we use this RET finding safely in this person?

• the RET result is clear and matches the tumor story
• the disease has spread and needs treatment through the whole body
• older treatment no longer holds the disease well
• thyroid cancer needs a medicine plan, not only surgery or local treatment
• the family wants another oncology opinion before starting a long capsule course
• blood pressure, liver tests, heart rhythm, bleeding risk, or wound healing need a careful look first

The useful question is not “is the drug strong?” It is: what are we trying to change now, and can the patient get through the treatment without too much harm?

What needs to be checked before treatment

A short note with “RET” in it is not enough. The doctor needs the file open, not just the drug name.

• the exact diagnosis and biopsy report
• the RET report, including what kind of change was found
• recent scans that show where the disease is now
• the full list of earlier treatment and why each step stopped
• blood pressure readings and heart history
• ECG information if rhythm problems or rhythm-related medicines are part of the case
• liver and kidney blood tests
• bleeding history, bruising, recent procedures, and any wound that is still healing
• the full medicine list, including supplements and pharmacy drugs

Sometimes the first job is not the cancer capsule. It may be fixing blood pressure, checking the rhythm, waiting for a wound to heal, or repeating a molecular test that no longer answers the current question.

How treatment with selpercatinib goes

Selpercatinib is taken by mouth. The dose and timing come from the oncologist. No skipped-dose experiments. No restart from an old box after a break.

The patient may be at home, but the treatment is still active cancer care. During the first weeks, the team watches pressure, liver tests, bowel symptoms, swelling, dizziness, bleeding, and how the person feels day to day.

During treatment, the team usually follows:

• daily tolerance and new symptoms
• blood pressure at home and in clinic
• liver blood tests
• heart rhythm checks when the history or medicines make that relevant
• swelling, loose stool, dry mouth, appetite, and weight
• bruising, bleeding, or slow wound healing
• scan timing and what the scan is meant to answer

A difficult week does not always close the door on Retevmo. Sometimes the answer is a short hold, a dose change, support medicine, or a closer look at another cause.

Possible side effects

Retevmo can feel different from one patient to another. One person notices swelling. Another has bowel trouble. Another feels fine but the liver tests rise.

• swelling of the legs, face, or hands
• loose stool, nausea, belly discomfort, or dry mouth
• tiredness, low appetite, weakness, or dizziness
• higher blood pressure
• changes in liver blood tests
• rash or skin discomfort
• headache or feeling unsteady
• heart rhythm concerns in some patients
• bruising or bleeding
• slower healing after surgery or a procedure

Small symptoms should not be hidden for a week. With this kind of drug, early contact often keeps a manageable problem from becoming the reason treatment stops.

When the treating team needs to know fast

Call or message the team the same day if any of this starts:

• strong or repeated loose stool
• very high blood pressure, severe headache, or vision changes
• fainting, strong dizziness, or a racing or irregular heartbeat
• yellow eyes, dark urine, or pain high on the right side of the belly
• blood in stool, urine, vomit, or any unusual bleeding
• fast swelling of the legs, face, or hands
• shortness of breath, chest pain, or sudden severe weakness
• a quick drop in overall strength

Do not try to prove at home whether Retevmo caused it. The team needs to sort that out early.

Why selpercatinib is not right for everyone

Selpercatinib can be a strong option in the right RET story. It is still not a general answer for every lung cancer, thyroid cancer, or solid tumor.

• the RET result is missing, unclear, or does not match the disease story
• another treatment route fits the case better
• blood pressure is already difficult to control
• heart rhythm problems make the plan risky
• liver tests are not safe enough for a clean start
• there was recent surgery or a wound is not healing well
• the medicine list creates safety problems
• the patient is too weak for a long capsule course right now

Choosing something else does not mean Retevmo is a bad drug. It may simply be the wrong moment or the wrong burden for that patient.

Can selpercatinib be combined with other treatments

Sometimes Retevmo is one part of a wider route. It is not added just to make a plan look stronger.

• after older systemic treatment
• after surgery or radiation, if the disease later needs body-wide control
• with support for diarrhea, pressure, pain, skin symptoms, or mouth dryness
• after checking the medicine list for conflicts
• as an option to compare with another targeted drug or a clinical trial

The order matters. Some patients need time. Some should not lose time. The file, not the drug name, decides that discussion.

What no quick response can mean

A patient may start capsules and feel no clear change in the first weeks. That does not answer the cancer question by itself.

Sometimes the scan later shows smaller areas. Sometimes the better news is quieter: the disease has stopped running ahead for a while. For advanced disease, that can still matter.

The doctor looks at scans, symptoms, pressure, liver tests, side effects, and the speed of the disease before treatment. One number alone is not enough to decide whether to continue, hold, or change course.

Oncology consultation in Israel about selpercatinib

At Tel Aviv Medical Clinic, Retevmo can be discussed as part of a second opinion for a RET-positive tumor. This may help when the family has a molecular report but does not understand why this capsule was offered now.

The consultation can help clarify:

• whether the RET result is enough for this decision
• which diagnosis and treatment line are being discussed
• what older treatment already showed
• what to check before the first dose
• which risks matter most: pressure, liver, rhythm, bleeding, wounds, or interactions
• which questions should go back to the treating oncologist

We do not prescribe treatment remotely and we do not replace the treating doctor. The purpose is to organize the case and make the next medical conversation clearer.

Frequently asked questions – answered by Dr. Stefanska

1. Is Retevmo chemotherapy?

No. It is not classic chemotherapy. Retevmo is a targeted capsule used only when the tumor report gives a real RET reason.

But I would not call it a light capsule. Blood pressure, liver tests, heart rhythm, bleeding, wound healing, and daily strength still need attention.

2. Why is the RET test so important?

Because without it, the plan is only guessing. RET is not one simple word. A report may describe a fusion, a mutation, or another finding, and that detail changes the discussion.

I want to see the actual report: what was found, how it was tested, from which sample, and whether the result still fits the disease today.

3. Which tumors can bring up Retevmo?

Most often the talk is about lung cancer with a RET rearrangement or thyroid cancer with a RET change. Sometimes another solid tumor can enter the discussion too.

The tumor name is not enough for me. I need the biopsy, the RET report, the scans, and the old treatment story before I can say whether this route makes sense.

4. Why do we watch blood pressure during treatment?

Because pressure can rise even in a person who never worried about it before. The patient may feel normal while the numbers are already too high.

That does not always mean stopping Retevmo. It does mean the team needs the numbers early, not after weeks of guessing.

5. What should I do with diarrhea or strong weakness?

Tell the team. Do not wait several days. Loose stool can turn into dehydration, and weakness may come from more than one cause.

Sometimes it is the drug. Sometimes it is pressure, liver tests, infection, poor eating, or another medicine. The team has to check.

6. Can selpercatinib be used after other treatment?

Sometimes yes. But first I need the old story: which drugs were used, how long they helped, why they stopped, and what the newest scans show.

If many treatments have already passed, the molecular result may also need another look. Old papers do not always answer the current question.

7. What should be sent for a second opinion about Retevmo?

Send the biopsy report, the RET test, recent scans, blood work, liver tests, pressure records if available, ECG if there were rhythm concerns, and the full medicine list.

Add a short timeline: diagnosis date, treatments used, what helped, what stopped helping, and the side effects that caused the most trouble.

Important information

This page is general medical information. It is not a treatment prescription. Selpercatinib should be discussed only after the doctor reviews the diagnosis, RET report, scans, previous treatment, blood pressure, liver tests, heart rhythm history, medicines, and the patient’s general condition.

Do not start, stop, or change treatment without the treating doctor.

Contacts

For a consultation about Selpercatinib:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108